Cancer Monitoring

The BEST tool for monitoring cancer in cats and dogs: Minimal sample, low cost, effective.

VDI’s Cancer Panels can be the most effective tool you have for monitoring cancer patients. The low-cost and minimal sample requirement makes it a clear choice for managing your patients.

Scroll down for Case Studies, Common Applications, and Report Interpretation

vdi cancer panel monitoring chart descriptions

Monitoring Overview

Thymidine Kinase, type 1 (TK1) is a DNA proliferation enzyme and is elevated in dividing cancer cells. During therapy (chemo/surgery) the source of TK1 is reduced/eliminated and serum TK1 (sTK1) levels will fall. Conversely, growing cancer cells during disease recurrence will increase sTK1 levels. Suspected undiagnosed patients can also be followed in the same manner. This makes the Cancer Panel an effective tool for patient monitoring.

When combined with an inflammatory marker (CRP/HPT), the change and relationship between both markers is indicative of disease activity.


Common Applications:

  • Indolent cancer tracking
  • Chemotherapy management
  • Post mass-removal confirmation
  • Metastatic disease
  • Remission monitoring

Not recommended for:

  • Cutaneous masses
  • Mast Cell Tumors (stage I)
  • Brain tumors

Interpreting the Report

Scroll down to learn more about what’s included with VDI cancer monitoring reports.

Reports Include:

  • TK1 result
  • C-Reactive Protein (dog) or Haptoglobin (cat) result
  • Neoplasia Index (NI) – for initial diagnosis if required
  • Trending Arrows
  • Significant Change Arrows
  • Interpretive Comments
  • Recommended Retest Window
  • Contextual Review (must provide context on requisition form)

Sample Monitoring Reports:

Case Studies

Scroll the case studies below, or click the links:


Interpreting the Results

VDI Cancer Panel monitoring reports come with a number of important indicators. Reports come with general comments reflecting the information in the tables below, but each cancer panel report still receives a contextual review by the lab for additional comments/interpretation as needed.

Significant Change

A change of 40% or more from prior. Studies show this level of change can precede cancer recurrence.

What does it signify?What does it mean?
significant reduction or improvement of at least 40%indicates therapy is effective in reducing or eliminating the tumor or inflammation
significant increase in TK1 however below the 9U/L thresholdindicates the level of change is worth watching – changes in clinical status of the patient is important
significant increase in the biomarker above critical thresholdsstudies show this level of change in TK1 often precedes cancer recurrence

Trending

2 or more data points in the same direction. Short-term trending events are the most valuable in confirming cancer recurrence.

What does it signify?What does it mean?
significant reduction or improvement of at least 40%indicates therapy is effective in reducing or eliminating the tumor or inflammation
significant increase in TK1 however below the 9U/L thresholdindicates the level of change is worth watching – changes in clinical status of the patient is important
significant increase in the biomarker above critical thresholdsstudies show this level of change in TK1 often precedes cancer recurrence

Retest Window

With VDI Cancer Panel monitoring reports, you may also receive a retest window recommendation. These recommendations are to help ensure you are rechecking TK1 and CRP/HPT levels in a timeframe that will have the most impact for patient evaluation. These windows are automatically calculated based on various factors and when the current sample was collected.